Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 9, Number 12—December 2003

Dispatch

Visceral Leishmaniasis Treatment, Italy

Luigi Gradoni*Comments to Author , Marina Gramiccia*, and Aldo Scalone*
Author affiliations: *Istituto Superiore di Sanità, Rome, Italy

Main Article

Figure 2

Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001.

Figure 2. Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO